25 May 2013
Keywords: merck, co, cancidas, comparable, ambisome, ifi, drug
Article | 01 October 2007
US drug major Merck & Co's Cancidas (caspofungin acetate) demonstrated a safety and efficacy profile generally similar to Gilead Sciences'
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 October 2007
24 May 2013
© 2013 thepharmaletter.com